Coherus BioSciences (NASDAQ:CHRS) Sets New 52-Week Low at $13.70


Share on StockTwits

Coherus BioSciences, Inc. (NASDAQ:CHRS) shares hit a new 52-week low during trading on Monday . The company traded as low as $13.70 and last traded at $13.78, with a volume of 1171 shares traded. The stock had previously closed at $13.95.

CHRS has been the subject of a number of recent research reports. Citigroup lowered their price objective on Coherus BioSciences from $30.00 to $27.00 in a research note on Thursday, February 25th. Zacks Investment Research raised Coherus BioSciences from a “sell” rating to a “hold” rating in a research note on Friday, April 2nd. Finally, HC Wainwright decreased their price target on Coherus BioSciences from $33.00 to $29.00 and set a “buy” rating for the company in a research note on Wednesday, March 3rd. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $25.43.

The company has a 50 day moving average price of $15.26 and a 200-day moving average price of $17.25. The company has a market cap of $1.01 billion, a P/E ratio of 6.82, a PEG ratio of 9.34 and a beta of 1.57. The company has a quick ratio of 5.18, a current ratio of 5.45 and a debt-to-equity ratio of 1.58.

Coherus BioSciences (NASDAQ:CHRS) last announced its earnings results on Tuesday, February 23rd. The biotechnology company reported $0.12 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.25 by ($0.13). Coherus BioSciences had a net margin of 33.06% and a return on equity of 90.98%. The firm had revenue of $110.42 million for the quarter, compared to the consensus estimate of $114.90 million. On average, research analysts expect that Coherus BioSciences, Inc. will post 1.71 earnings per share for the current fiscal year.

In related news, CFO Jean-Frederic Viret sold 46,144 shares of the firm’s stock in a transaction dated Monday, January 25th. The stock was sold at an average price of $19.95, for a total transaction of $920,572.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Vladimir Vexler sold 114,240 shares of the firm’s stock in a transaction dated Tuesday, March 9th. The shares were sold at an average price of $16.25, for a total value of $1,856,400.00. The disclosure for this sale can be found here. Insiders have sold 162,884 shares of company stock valued at $2,821,823 in the last ninety days. Company insiders own 15.86% of the company’s stock.

Hedge funds and other institutional investors have recently made changes to their positions in the company. Financial Enhancement Group LLC purchased a new stake in shares of Coherus BioSciences during the fourth quarter valued at $26,000. Penserra Capital Management LLC lifted its holdings in shares of Coherus BioSciences by 171.3% during the fourth quarter. Penserra Capital Management LLC now owns 1,655 shares of the biotechnology company’s stock valued at $28,000 after purchasing an additional 1,045 shares during the last quarter. Baillie Gifford & Co. purchased a new stake in shares of Coherus BioSciences during the fourth quarter valued at $30,000. Veriti Management LLC purchased a new stake in shares of Coherus BioSciences during the fourth quarter valued at $33,000. Finally, Inspire Advisors LLC purchased a new stake in shares of Coherus BioSciences during the fourth quarter valued at $37,000.

About Coherus BioSciences (NASDAQ:CHRS)

Coherus BioSciences, Inc, a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its product candidate pipeline includes biosimilars of Humira, Avastin, and Lucentis.

Featured Article: How does a security become overbought?

Receive News & Ratings for Coherus BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coherus BioSciences and related companies with MarketBeat.com's FREE daily email newsletter.